Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Patent
1995-09-29
1997-04-29
Kulkosky, Peter F.
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
424647, A01N 5916, A61K 3326
Patent
active
056246684
ABSTRACT:
Ferric oxyhydroxide-dextran compositions for treating iron deficiency having ellipsoidal particles with a preferred molecular weight range of about 250,000 to 300,000 daltons.
REFERENCES:
patent: Re24642 (1959-04-01), London et al.
patent: 2820740 (1958-01-01), London et al.
patent: 2885393 (1959-05-01), Herb
patent: 3686397 (1972-08-01), Muller
patent: 3697502 (1972-10-01), Christensen
patent: 3908004 (1975-09-01), Kitching
patent: 4101435 (1978-07-01), Hasegawa et al.
patent: 4180567 (1979-12-01), Herb
patent: 4452773 (1984-06-01), Molday
patent: 4454773 (1984-06-01), Brunner et al.
patent: 4505726 (1985-03-01), Takeuchi et al.
patent: 4599405 (1986-07-01), Muekker et al.
patent: 4659697 (1987-04-01), Tanaka
patent: 4749695 (1988-06-01), Schwengers
patent: 4788281 (1988-11-01), Tosoni et al.
patent: 4927756 (1990-05-01), Schwengers
patent: 5102652 (1992-04-01), Groman et al.
patent: 5118513 (1992-06-01), Mehansho et al.
patent: 5248492 (1993-09-01), Groman et al.
patent: 5336506 (1994-08-01), Josephson et al.
patent: 5354350 (1994-10-01), Moore
P. Carthew et al., Hepatology, vol. 13, No. 3, pp. 534-539 (1991): Rapid Induction of Hepatic Fibrosis in the Gerbil After the Parenteral Administration of Iron-Dextran Complex.
L.M. Fletcher, et al., Gastroenterology, vol. 97, pp. 1011-1018 (1989): Effects of Iron Loading on Free Radical Scavenging Enzymes and Lipid Peroxidation in Rat Liver.
R.D. Hamstra et al., JAMA, vol. 243, No. 17, pp. 1726-1731 (1980): Intravenous Iron Dextran in Clinical Medicine.
P.A. Henderson et al., Blood, vol. 34, No. 3, pp. 357-375 (1969): Characteristics of Iron Dextran Utilization in Man.
T. O. Pitts et al., Nephron, vol. 22, pp. 316-321 (1978): Hemosiderosis Secondary to Chronic Parenteral Iron Therapy in Maintenance Hemodialysis Patients.
L. R. Weintraub et al., British Journal of Haemotology, vol. 59, pp. 321-331 (1985): Pathogenesis of Hepatic Fibrosis in Experimental Iron Overload.
Package Insert for INFeD (Iron Dextran Injection, USP).
Package Insert for Imferon (Iron Dextran Injection, USP).
1994 ASH Abstract Reproduction Form, 36th Annual Meeting, Nashville, TN (1994): "Pharmacokinetics of Iron Dextran In Iron Deficient Dialysis Patients: Evaluation and Comparison of Two Agents", by D. Van Wyck et al.
1994 ASH Abstract Reproduction Form, 36th Annual Meeting, Nashville, TN (1994): "Iron Mobilization Early After Iron Dextran Infusion in Hemodialysis Patients: Evaluation and Comparison of 2 Agents", by D. Van Wyck et al.
Helenek Mary J.
Lange Ralf A.
Lawrence Richard P.
Wu Chin
Kulkosky Peter F.
Luitpold Pharmaceuticals, Inc.
LandOfFree
Iron dextran formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Iron dextran formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Iron dextran formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703955